Last reviewed · How we verify
NCT06066450
Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis
trial testing Genoss® DES system, Genoss® Osfit system in Drug-eluting Stent in 1,000 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Genoss Co., Ltd. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 7 July 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Genoss® DES system, Genoss® Osfit system
Conditions studied
- Drug-eluting Stent — all drugs for Drug-eluting Stent →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Genoss Co., Ltd.
Who can join
19 and older, any sex, with Drug-eluting Stent or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this observational study is to evaluate the long-term effectiveness and safety of the OSFIT drug-eluting stent designed to facilitate procedures in coronary artery lesions. Additionally, the study aims to verify the accuracy of stent placement in the lesion of interest using Optical Coherence Tomography (OCT) among subgroups of participants. The primary endpoint was defined as the composite of target lesion failure (TLF) at the 12-month mark, including cardiac death, target vessel myocardial infarction (MI), or target lesion revascularization.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Demystifying the Quandary of Ostial Stenting.
Dash D, Mody R, Dash U, Mylarappa YP, et al · · 2024 · cited 1× · PMID 39434365 · DOI 10.4070/kcj.2024.0158
Verify or expand the search:
- PubMed search for NCT06066450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Genoss Co., Ltd. trials
Trials by the same sponsor.
- NCT07425171 — Safety and Effectiveness of GENOSS PCB in Patients With Long Femoropopliteal Lesion · not yet recruiting
- NCT07399080 — Clinical Outcomes of GENOSS PCB for Femoropopliteal Artery Disease · enrolling by invitation
- NCT07431437 — One-Year Results of GENOSS PCB Real-World Study in Femoropopliteal Artery Disease · enrolling by invitation
- NCT07159087 — The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients Wit · NA · enrolling by invitation
- NCT07158307 — Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06066450 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genoss Co., Ltd.
- Last refreshed: 1 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06066450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing